Project Grant R01DK148711
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $850K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $743,862 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on macrophage mitochondrial metabolism and metabolic dysfunction-associated steatotic liver disease (MASLD). The research investigates how alterations in macrophage composition and function contribute to MASH (metabolic dysfunction-associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts Institute of Technology $518,779 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Listing Project Grant R01DK145857). The award funds research to define the molecular signals that drive liver regeneration following injury. The work investigates how the body senses liver injury and stimulates hepatocyte proliferation, with focus on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beth Israel Deaconess Medical Center $164,484 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of DNAJC22 in metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research exploring DNAJC22, a gene of unknown function identified through genome-wide CRISPR-Cas9 screening and human genetic association studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts Institute of Technology $149,190 on December 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the ferrostatic role of adipose tissue macrophages in iron homeostasis and metabolic regulation. The research elucidates tissue-level iron handling functions of vasculature-associated macrophages (VAMs) by identifying primary iron uptake pathways...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1,677,898 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop fat and iron-corrected quantitative MRI T1 mapping as a non-invasive biomarker for evaluating chronic liver disease, particularly metabolic-associated steatohepatitis (MASH). The project addresses the clinical need for non-invasive assessment of liver pathology...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $761,577 on March 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of histone methylation marks in blood cell development. The research interrogates how H3K4 and H3K27 histone methylation regulate hematopoiesis using novel histone mutant transgenic tools. Preliminary work demonstrated that H3K4 methylation is...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $874,741 on June 1, 2026, to investigate transcriptional mechanisms of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research identifies and characterizes transcription factors that regulate collagen production in hepatic stellate cells, a key driver of liver...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $639,990 to The University of Texas Health Science Center at San Antonio on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant R01DK144299). The recipient will investigate the role of oxidized phospholipids (OXPLs) in driving metabolic dysfunction-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC). Research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $835,752 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop molecular magnetic resonance imaging techniques for non-invasive assessment of inflammatory activity in inflammatory bowel disease. The project aims to create a rapid, sensitive imaging test that evaluates intestinal inflammation anywhere in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas MD Anderson Cancer Center $151,136.00 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct multi-omic analyses of the gut microbiome and its relationship to metabolic dysfunction-associated steatotic liver disease (MASLD). The research integrates metagenomic, metabolomic, and metatranscriptomic analyses to explore microbial...